Hernández OJ, Olivera FEM, Pillán GA, Olivera FY, Cairo DR

Language: Spanish
References: 20
Page: 1306-1319
PDF size: 315.82 Kb.

ABSTRACT

Primary tumors of the brain constitute a heterogeneous group of neoplasms with biological behavior and with a very different prognosis. Its incidence has increased in recent years in all age groups. A prospective descriptive study of 58 patients with primary brain tumors was performed, attended in the Radiotherapy office of the Vladimir Ilich Lenin Hospital Oncology in the period from November 2014 to May 2017, with the objective of determining the physical symptoms and Cognitive manifestations in patients treated for primary brain tumors. The variables of age and sex, histological diagnosis, cancer treatment, physical symptoms and cognitive manifestations were characterized. The age group between 40 and 59 years was the most affected (51.72%), being in the most frequent male sex this pathology (65.52%). The histological type that predominated was astrocytoma in 77.11%. Radiation therapy was used in 100% of patients, and concurrent to nimotuzumab in 43 patients. The most frequent physical symptoms were sleep disorders (39.28%), and within the cognitive manifestations identified visual problems reached 35%. The physical symptoms and cognitive manifestations produced, either by the primary tumor or by the cancer treatment in patients with primary brain tumors, are factors that negatively influence the quality of life of these patients.

REFERENCES

1. Tumores pediátricos del sistem

2. Essig M, Anzalone N, Combs SE, Dörfler A, Lee SK, Picozzi P, et al. MR imaging of neoplastic central nervous system lesions: Review and recommendations for current practice. Am J Neuroradiol 2012; 33(5): 803-17.

3. Attia A, Page BR, Lesser GJ, Chan M. Treatment of radiation-induced cognitive decline. Curr Treat Options Oncol 2014; 15(4): 539-50.

4. McNeill KA. Epidemiology of brain tumors. Neurol Clin 2016; 34(4): 981-98.

5. Cayuela N, Simo M. Neurotoxicidad cognitiva inducida por la radioterapia cerebral en adultos. Rev Neurol 2019; 68(4): 160-168.

6. Edelstein K, Richard NM, Bernstein LJ. Neurocognitive impact of cranial radiation in adults with cancer: an update of recent findings. Curr Opin Support Palliat Care 2017; 11(1): 32-37.

7. Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131(6): 803-20.

8. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol 2016; 18(Suppl 5): S1-75.

9. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 2016; 17(9): 383-91.

10. Fathi A-R, Roelcke U. Meningioma. Curr Neurol Neurosci Rep 2013; 13(4): 337.

11. Rapalino O, Batchelor T, González RG. Intra-axial brain tumors. Handb Clin Neurol 2016; 135: 253-74.

12. Rapalino O, Smirniotopoulos JG. Extra-axial brain tumors. Handb Clin Neurol 2016; 135: 275-91.

13. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 2017; 134(4): 521-35.

14. Buttrick S, Shah AH, Komotar RJ, Ivan ME. Management of atypical and anaplastic meningiomas. Neurosurg Clin N Am 2016; 27(2): 239-47.

15. Spasic M, Pelargos PE, Barnette N, Bhatt NS, Lee SJ, Ung N, et al. Incidental Meningiomas: Management in the Neuroimaging Era. Neurosurg Clin N Am 2016; 27(2): 229-38.

16. Noorani I, Sanai N. Surgical management of incidental gliomas. Neurosurg Clin N Am 2017; 28(3): 397-406.

17. Baumert BG, Hegi ME, Van den Bent MJ, Von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2016; 17(11): 1521-32.

18. Suarez Martínez G, Salva Camaño SN, Piedra Sierra P, Iglesias Castillo B, Toledo Jiménez C, Solomón Cardona MT, et al. Seguridad y efectividad del nimotuzumab en los pacientes con tumores gliales malignos. Rev Cubana Neurol Neurocir 2015; 5(2): 123–32.

19. Ocampo Navia M, Gómez Vega J, Feo Lee O. Epidemiología y caracterización general de los tumores cerebrales primarios en el adulto. Universitas Médicas 2019; 60(1): 1-14.

20. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 2012; 14(11): 1316-24.